Table 1:
Baseline Patient Characteristics
| Aspirin Therapy |
Statin Therapy |
||||||
|---|---|---|---|---|---|---|---|
| Total | Secondary Prevention | Primary Prevention w/o Guideline Indication | Primary Prevention with Guideline Indication | Secondary Prevention | Primary Prevention w/o Guideline Indication | Primary Prevention with Guideline Indication | |
| Characteristic | N= 368 | N = 41 | N = 202 | N = 85 | N = 35 | N = 228 | N = 54 |
| Mean Age (years) | 52.8 ± 11.8 | 60.1 ± 12.7 | 48.6 ± 9.8 | 58.9 ± 11.6 | 60.3 ± 10.9 | 51.2 ± 11.4 | 55.0 ± 12.3 |
| Male sex – n (%) | 226 (61) | 26 (63) | 111 (55) | 69 (81) | 22 (63) | 138 (61) | 38 (70) |
| Hypertension – n (%) | 145 (39) | 25 (61) | 57 (28) | 50 (59) | 21 (61) | 78 (34) | 25 (46) |
| Smoking – n (%) | 180 (49) | 23 (56) | 83 (41) | 58 (68) | 19 (54) | 108 (47) | 30 (56) |
| Diabetes Mellitus – n (%) | 40 (11) | 6 (15) | 1 (1) | 30 (35) | 6 (17) | 9 (4) | 19 (35) |
| Vascular Disease (TIA/CVA/PAD) – n (%) | 13 (4) | 11 (27) | 0 (0) | 0 (0) | 10 (29) | 1 (0.5) | 0 (0) |
| Acute Coronary Syndrome - n (%) | 31 (8) | 31 (76) | 0 (0) | 0 (0) | 26 (74) | 3 (1) | 0 (0) |
| FRS category, n (%) | |||||||
| <10% | 251 (68) | 22 (54) | 202 (100) | 16 (19) | 20 (57) | 190 (83) | 24 (44) |
| 10% – 20% | 62 (17) | 11 (27) | 0 (0) | 49 (58) | 9 (26) | 31 (14) | 17 (31) |
| >20% | 26 (7) | 7 (17) | 0 (0) | 17 (20) | 6 (17) | 5 (2) | 13 (24) |
| Dyslipidemia – n (%) | 135 (37) | 24 (59) | 61 (30) | 40 (47) | 21 (60) | 76 (33) | 21 (39) |
| Total Cholesterol (mg/dl) | 195 ± 42 | 189 ± 42 | 196 ± 40 | 195 ± 48 | 195 ± 41 | 186 ± 37 | 231 ± 47 |
| LDL Cholesterol (mg/dl) | 114 ± 37 | 111 ± 38 | 116 ± 40 | 112 ± 37 | 117 ± 35 | 106 ± 32 | 146 ± 42 |
| HDL Cholesterol (mg/dl) | 51 ± 15 | 45 ± 12 | 54 ± 16 | 46 ± 12 | 46 ± 12 | 53 ± 16 | 48 ± 12 |
*
Plus-minus values are means ± SD.
TIA: Transient Ischemic Attack, CVA: Cerebrovascular Accident, PAD: Peripheral Arterial Disease, FRS: 10-year Framingham Risk Score